Discover how the experimental drug lepodisiran dramatically lowers lipoprotein(a) levels, potentially transforming treatment ...

The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk ...

The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...

An intensive three-drug regimen of heart medications did not significantly impact the rate of serious cardiovascular events ...

(Yicai) March 26 -- Shares of Hengrui Pharmaceuticals rose after the Chinese firm granted US-Canadian pharma giant Merck ...

TAKING two common drugs together could slash your levels of ‘bad’ cholesterol and lower the risk of death from heart attack ...

Eli Lilly is developing a groundbreaking drug, lepodisiran, to combat high LPA cholesterol levels prevalent in South Asians, ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Ages 30 to 39: One to five years of antidepressant use were around three times more likely to suffer sudden cardiac death.

Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, ...